nodes	percent_of_prediction	percent_of_DWPC	metapath
Methyldopa—ADRA2A—Amitriptyline—migraine	0.266	1	CbGbCtD
Methyldopa—DDC—pineal body—migraine	0.0208	0.224	CbGeAlD
Methyldopa—DDC—nerve—migraine	0.0151	0.163	CbGeAlD
Methyldopa—ADRA2A—peripheral nervous system—migraine	0.00654	0.0703	CbGeAlD
Methyldopa—DDC—brainstem—migraine	0.0065	0.0698	CbGeAlD
Methyldopa—COMT—trigeminal ganglion—migraine	0.00486	0.0522	CbGeAlD
Methyldopa—COMT—brainstem—migraine	0.0043	0.0462	CbGeAlD
Methyldopa—Cardiac failure congestive—Propranolol—migraine	0.00416	0.00719	CcSEcCtD
Methyldopa—Endocrine disorder—Valproic Acid—migraine	0.00409	0.00706	CcSEcCtD
Methyldopa—Liver injury—Valproic Acid—migraine	0.00403	0.00696	CcSEcCtD
Methyldopa—Eosinophilia—Amitriptyline—migraine	0.00397	0.00685	CcSEcCtD
Methyldopa—Amenorrhoea—Valproic Acid—migraine	0.00386	0.00666	CcSEcCtD
Methyldopa—Pancytopenia—Amitriptyline—migraine	0.00381	0.00657	CcSEcCtD
Methyldopa—Erectile dysfunction—Amitriptyline—migraine	0.00369	0.00637	CcSEcCtD
Methyldopa—Weight increased—Amitriptyline—migraine	0.00365	0.0063	CcSEcCtD
Methyldopa—DDC—head—migraine	0.00359	0.0386	CbGeAlD
Methyldopa—COMT—cardiovascular system—migraine	0.00351	0.0377	CbGeAlD
Methyldopa—Bone marrow depression—Topiramate—migraine	0.00351	0.00605	CcSEcCtD
Methyldopa—Jaundice—Amitriptyline—migraine	0.00348	0.00601	CcSEcCtD
Methyldopa—Vasculitis—Valproic Acid—migraine	0.00348	0.006	CcSEcCtD
Methyldopa—DDC—nervous system—migraine	0.00341	0.0366	CbGeAlD
Methyldopa—Toxic epidermal necrolysis—Propranolol—migraine	0.0034	0.00587	CcSEcCtD
Methyldopa—Psychotic disorder—Verapamil—migraine	0.00339	0.00586	CcSEcCtD
Methyldopa—Agranulocytosis—Amitriptyline—migraine	0.00334	0.00576	CcSEcCtD
Methyldopa—DDC—central nervous system—migraine	0.00328	0.0352	CbGeAlD
Methyldopa—Hepatitis—Amitriptyline—migraine	0.00321	0.00554	CcSEcCtD
Methyldopa—Amenorrhoea—Gabapentin—migraine	0.0032	0.00553	CcSEcCtD
Methyldopa—Orthostatic hypotension—Verapamil—migraine	0.00317	0.00548	CcSEcCtD
Methyldopa—Erectile dysfunction—Propranolol—migraine	0.00301	0.00519	CcSEcCtD
Methyldopa—Angina pectoris—Verapamil—migraine	0.00292	0.00505	CcSEcCtD
Methyldopa—Nightmare—Timolol—migraine	0.00292	0.00503	CcSEcCtD
Methyldopa—Infestation—Propranolol—migraine	0.00291	0.00502	CcSEcCtD
Methyldopa—Infestation NOS—Propranolol—migraine	0.00291	0.00502	CcSEcCtD
Methyldopa—Endocrine disorder—Topiramate—migraine	0.00285	0.00493	CcSEcCtD
Methyldopa—Dopamine—HTR7—migraine	0.00281	0.311	CrCbGaD
Methyldopa—Erectile dysfunction—Verapamil—migraine	0.00277	0.00477	CcSEcCtD
Methyldopa—Agranulocytosis—Propranolol—migraine	0.00272	0.00469	CcSEcCtD
Methyldopa—Colitis—Gabapentin—migraine	0.0027	0.00466	CcSEcCtD
Methyldopa—Amenorrhoea—Topiramate—migraine	0.00269	0.00465	CcSEcCtD
Methyldopa—Bradycardia—Propranolol—migraine	0.00266	0.00459	CcSEcCtD
Methyldopa—DDC—SIDS Susceptibility Pathways—ATP1A3—migraine	0.00262	0.0496	CbGpPWpGaD
Methyldopa—Jaundice—Verapamil—migraine	0.00261	0.0045	CcSEcCtD
Methyldopa—DDC—brain—migraine	0.0026	0.028	CbGeAlD
Methyldopa—Gynaecomastia—Gabapentin—migraine	0.00252	0.00434	CcSEcCtD
Methyldopa—Leukopenia—Amitriptyline—migraine	0.0025	0.00432	CcSEcCtD
Methyldopa—ADRA2A—trigeminal ganglion—migraine	0.00247	0.0266	CbGeAlD
Methyldopa—Bradycardia—Verapamil—migraine	0.00245	0.00422	CcSEcCtD
Methyldopa—Cardiac disorder—Propranolol—migraine	0.00242	0.00418	CcSEcCtD
Methyldopa—Cardiac failure congestive—Timolol—migraine	0.00242	0.00417	CcSEcCtD
Methyldopa—Nasal congestion—Timolol—migraine	0.00241	0.00415	CcSEcCtD
Methyldopa—Psychotic disorder—Valproic Acid—migraine	0.00241	0.00415	CcSEcCtD
Methyldopa—Hepatitis—Verapamil—migraine	0.0024	0.00415	CcSEcCtD
Methyldopa—COMT—head—migraine	0.00238	0.0255	CbGeAlD
Methyldopa—Libido decreased—Timolol—migraine	0.00236	0.00408	CcSEcCtD
Methyldopa—Mental disorder—Propranolol—migraine	0.00229	0.00395	CcSEcCtD
Methyldopa—Oedema—Amitriptyline—migraine	0.00228	0.00393	CcSEcCtD
Methyldopa—Eczema—Gabapentin—migraine	0.00227	0.00392	CcSEcCtD
Methyldopa—COMT—nervous system—migraine	0.00225	0.0242	CbGeAlD
Methyldopa—Cardiac failure congestive—Gabapentin—migraine	0.00225	0.00389	CcSEcCtD
Methyldopa—Orthostatic hypotension—Valproic Acid—migraine	0.00225	0.00388	CcSEcCtD
Methyldopa—Thrombocytopenia—Amitriptyline—migraine	0.00223	0.00385	CcSEcCtD
Methyldopa—DDC—SIDS Susceptibility Pathways—HTR3A—migraine	0.00223	0.0422	CbGpPWpGaD
Methyldopa—Epinephrine—TNF—migraine	0.00223	0.247	CrCbGaD
Methyldopa—Breast disorder—Valproic Acid—migraine	0.00223	0.00384	CcSEcCtD
Methyldopa—ADRA2A—Monoamine GPCRs—HTR1D—migraine	0.00222	0.042	CbGpPWpGaD
Methyldopa—Toxic epidermal necrolysis—Valproic Acid—migraine	0.00222	0.00383	CcSEcCtD
Methyldopa—Libido decreased—Gabapentin—migraine	0.0022	0.0038	CcSEcCtD
Methyldopa—Disturbance in sexual arousal—Timolol—migraine	0.00218	0.00375	CcSEcCtD
Methyldopa—COMT—central nervous system—migraine	0.00217	0.0233	CbGeAlD
Methyldopa—COMT—Neuronal System—KCNK18—migraine	0.00217	0.0409	CbGpPWpGaD
Methyldopa—Dopamine—HTR1A—migraine	0.00215	0.238	CrCbGaD
Methyldopa—COMT—cerebellum—migraine	0.00212	0.0228	CbGeAlD
Methyldopa—Eosinophilia—Valproic Acid—migraine	0.00211	0.00364	CcSEcCtD
Methyldopa—Pancreatitis—Valproic Acid—migraine	0.00209	0.0036	CcSEcCtD
Methyldopa—ADRA2A—Monoamine GPCRs—HTR2B—migraine	0.00207	0.0391	CbGpPWpGaD
Methyldopa—Paraesthesia—Amitriptyline—migraine	0.00205	0.00353	CcSEcCtD
Methyldopa—Disturbance in sexual arousal—Gabapentin—migraine	0.00203	0.0035	CcSEcCtD
Methyldopa—Liver function test abnormal—Timolol—migraine	0.00202	0.00349	CcSEcCtD
Methyldopa—Pancytopenia—Valproic Acid—migraine	0.00202	0.00349	CcSEcCtD
Methyldopa—Psychotic disorder—Gabapentin—migraine	0.00199	0.00344	CcSEcCtD
Methyldopa—Breast disorder—Timolol—migraine	0.00198	0.00342	CcSEcCtD
Methyldopa—Constipation—Amitriptyline—migraine	0.00195	0.00336	CcSEcCtD
Methyldopa—Weight increased—Valproic Acid—migraine	0.00194	0.00334	CcSEcCtD
Methyldopa—Unspecified disorder of skin and subcutaneous tissue—Propranolol—migraine	0.00192	0.00332	CcSEcCtD
Methyldopa—Eczema—Topiramate—migraine	0.00191	0.0033	CcSEcCtD
Methyldopa—Nasal congestion—Topiramate—migraine	0.00189	0.00325	CcSEcCtD
Methyldopa—Liver function test abnormal—Gabapentin—migraine	0.00189	0.00325	CcSEcCtD
Methyldopa—ADRA2A—Amine ligand-binding receptors—HTR1D—migraine	0.00187	0.0353	CbGpPWpGaD
Methyldopa—Libido decreased—Topiramate—migraine	0.00185	0.0032	CcSEcCtD
Methyldopa—Angina pectoris—Timolol—migraine	0.00185	0.00319	CcSEcCtD
Methyldopa—Breast disorder—Gabapentin—migraine	0.00185	0.00318	CcSEcCtD
Methyldopa—Infection—Propranolol—migraine	0.00184	0.00318	CcSEcCtD
Methyldopa—Dopamine—SLC6A4—migraine	0.00184	0.204	CrCbGaD
Methyldopa—Nervous system disorder—Propranolol—migraine	0.00182	0.00314	CcSEcCtD
Methyldopa—Skin disorder—Propranolol—migraine	0.0018	0.00311	CcSEcCtD
Methyldopa—Body temperature increased—Amitriptyline—migraine	0.0018	0.00311	CcSEcCtD
Methyldopa—Hepatobiliary disease—Valproic Acid—migraine	0.0018	0.0031	CcSEcCtD
Methyldopa—Myalgia—Verapamil—migraine	0.00178	0.00307	CcSEcCtD
Methyldopa—Arthralgia—Verapamil—migraine	0.00178	0.00307	CcSEcCtD
Methyldopa—Agranulocytosis—Valproic Acid—migraine	0.00177	0.00306	CcSEcCtD
Methyldopa—Eosinophilia—Gabapentin—migraine	0.00175	0.00302	CcSEcCtD
Methyldopa—Erectile dysfunction—Timolol—migraine	0.00175	0.00301	CcSEcCtD
Methyldopa—ADRA2A—Amine ligand-binding receptors—HTR2B—migraine	0.00174	0.0328	CbGpPWpGaD
Methyldopa—Bradycardia—Valproic Acid—migraine	0.00173	0.00299	CcSEcCtD
Methyldopa—Pancreatitis—Gabapentin—migraine	0.00173	0.00299	CcSEcCtD
Methyldopa—COMT—brain—migraine	0.00172	0.0185	CbGeAlD
Methyldopa—Angina pectoris—Gabapentin—migraine	0.00172	0.00297	CcSEcCtD
Methyldopa—Oedema—Verapamil—migraine	0.00171	0.00295	CcSEcCtD
Methyldopa—Disturbance in sexual arousal—Topiramate—migraine	0.0017	0.00294	CcSEcCtD
Methyldopa—Infection—Verapamil—migraine	0.0017	0.00293	CcSEcCtD
Methyldopa—Psychotic disorder—Topiramate—migraine	0.00168	0.0029	CcSEcCtD
Methyldopa—Connective tissue disorder—Valproic Acid—migraine	0.00167	0.00289	CcSEcCtD
Methyldopa—Paraesthesia—Propranolol—migraine	0.00167	0.00288	CcSEcCtD
Methyldopa—Asthenia—Amitriptyline—migraine	0.00164	0.00282	CcSEcCtD
Methyldopa—Erectile dysfunction—Gabapentin—migraine	0.00163	0.00281	CcSEcCtD
Methyldopa—Weight increased—Gabapentin—migraine	0.00161	0.00277	CcSEcCtD
Methyldopa—Gastrointestinal disorder—Propranolol—migraine	0.0016	0.00277	CcSEcCtD
Methyldopa—Constipation—Propranolol—migraine	0.00159	0.00274	CcSEcCtD
Methyldopa—Liver function test abnormal—Topiramate—migraine	0.00159	0.00274	CcSEcCtD
Methyldopa—Agranulocytosis—Timolol—migraine	0.00158	0.00272	CcSEcCtD
Methyldopa—Infestation NOS—Gabapentin—migraine	0.00157	0.00272	CcSEcCtD
Methyldopa—Infestation—Gabapentin—migraine	0.00157	0.00272	CcSEcCtD
Methyldopa—Orthostatic hypotension—Topiramate—migraine	0.00157	0.00271	CcSEcCtD
Methyldopa—Diarrhoea—Amitriptyline—migraine	0.00156	0.00269	CcSEcCtD
Methyldopa—Musculoskeletal discomfort—Verapamil—migraine	0.00156	0.00268	CcSEcCtD
Methyldopa—Breast disorder—Topiramate—migraine	0.00155	0.00268	CcSEcCtD
Methyldopa—Toxic epidermal necrolysis—Topiramate—migraine	0.00155	0.00267	CcSEcCtD
Methyldopa—Angiopathy—Valproic Acid—migraine	0.00155	0.00267	CcSEcCtD
Methyldopa—Bradycardia—Timolol—migraine	0.00154	0.00267	CcSEcCtD
Methyldopa—Mediastinal disorder—Valproic Acid—migraine	0.00154	0.00265	CcSEcCtD
Methyldopa—Jaundice—Gabapentin—migraine	0.00153	0.00265	CcSEcCtD
Methyldopa—Paraesthesia—Verapamil—migraine	0.00153	0.00265	CcSEcCtD
Methyldopa—Dizziness—Amitriptyline—migraine	0.00151	0.0026	CcSEcCtD
Methyldopa—Abdominal distension—Topiramate—migraine	0.00149	0.00258	CcSEcCtD
Methyldopa—Mental disorder—Valproic Acid—migraine	0.00149	0.00258	CcSEcCtD
Methyldopa—Connective tissue disorder—Timolol—migraine	0.00149	0.00257	CcSEcCtD
Methyldopa—Hepatobiliary disease—Gabapentin—migraine	0.00149	0.00257	CcSEcCtD
Methyldopa—Eosinophilia—Topiramate—migraine	0.00147	0.00254	CcSEcCtD
Methyldopa—Body temperature increased—Propranolol—migraine	0.00147	0.00253	CcSEcCtD
Methyldopa—Flatulence—Valproic Acid—migraine	0.00146	0.00252	CcSEcCtD
Methyldopa—Constipation—Verapamil—migraine	0.00146	0.00252	CcSEcCtD
Methyldopa—Pancreatitis—Topiramate—migraine	0.00146	0.00251	CcSEcCtD
Methyldopa—Vomiting—Amitriptyline—migraine	0.00145	0.0025	CcSEcCtD
Methyldopa—Angina pectoris—Topiramate—migraine	0.00145	0.0025	CcSEcCtD
Methyldopa—Bradycardia—Gabapentin—migraine	0.00144	0.00248	CcSEcCtD
Methyldopa—Rash—Amitriptyline—migraine	0.00144	0.00248	CcSEcCtD
Methyldopa—Dermatitis—Amitriptyline—migraine	0.00144	0.00248	CcSEcCtD
Methyldopa—Headache—Amitriptyline—migraine	0.00143	0.00246	CcSEcCtD
Methyldopa—Hepatitis—Gabapentin—migraine	0.00141	0.00244	CcSEcCtD
Methyldopa—Pancytopenia—Topiramate—migraine	0.00141	0.00243	CcSEcCtD
Methyldopa—Cardiac disorder—Timolol—migraine	0.00141	0.00243	CcSEcCtD
Methyldopa—Connective tissue disorder—Gabapentin—migraine	0.00139	0.0024	CcSEcCtD
Methyldopa—COMT—Transmission across Chemical Synapses—CACNA1A—migraine	0.00138	0.0261	CbGpPWpGaD
Methyldopa—Angiopathy—Timolol—migraine	0.00138	0.00238	CcSEcCtD
Methyldopa—Hypersensitivity—Propranolol—migraine	0.00137	0.00236	CcSEcCtD
Methyldopa—Erectile dysfunction—Topiramate—migraine	0.00137	0.00236	CcSEcCtD
Methyldopa—Mediastinal disorder—Timolol—migraine	0.00137	0.00236	CcSEcCtD
Methyldopa—Nausea—Amitriptyline—migraine	0.00135	0.00234	CcSEcCtD
Methyldopa—Weight increased—Topiramate—migraine	0.00135	0.00233	CcSEcCtD
Methyldopa—ADRA2A—Monoamine GPCRs—HTR1B—migraine	0.00135	0.0255	CbGpPWpGaD
Methyldopa—Asthenia—Propranolol—migraine	0.00133	0.0023	CcSEcCtD
Methyldopa—Mental disorder—Timolol—migraine	0.00133	0.00229	CcSEcCtD
Methyldopa—Leukopenia—Valproic Acid—migraine	0.00133	0.00229	CcSEcCtD
Methyldopa—Infestation NOS—Topiramate—migraine	0.00132	0.00228	CcSEcCtD
Methyldopa—Infestation—Topiramate—migraine	0.00132	0.00228	CcSEcCtD
Methyldopa—Cardiac disorder—Gabapentin—migraine	0.00131	0.00226	CcSEcCtD
Methyldopa—ADRA2A—Monoamine GPCRs—HTR1A—migraine	0.0013	0.0245	CbGpPWpGaD
Methyldopa—Mediastinal disorder—Gabapentin—migraine	0.00127	0.0022	CcSEcCtD
Methyldopa—Diarrhoea—Propranolol—migraine	0.00127	0.00219	CcSEcCtD
Methyldopa—Arthralgia—Valproic Acid—migraine	0.00126	0.00218	CcSEcCtD
Methyldopa—Myalgia—Valproic Acid—migraine	0.00126	0.00218	CcSEcCtD
Methyldopa—Hypersensitivity—Verapamil—migraine	0.00126	0.00217	CcSEcCtD
Methyldopa—Unspecified disorder of skin and subcutaneous tissue—Valproic Acid—migraine	0.00125	0.00216	CcSEcCtD
Methyldopa—ADRA2A—Monoamine GPCRs—HTR2C—migraine	0.00125	0.0237	CbGpPWpGaD
Methyldopa—Mental disorder—Gabapentin—migraine	0.00124	0.00214	CcSEcCtD
Methyldopa—Agranulocytosis—Topiramate—migraine	0.00124	0.00213	CcSEcCtD
Methyldopa—Dizziness—Propranolol—migraine	0.00123	0.00212	CcSEcCtD
Methyldopa—Asthenia—Verapamil—migraine	0.00123	0.00211	CcSEcCtD
Methyldopa—Flatulence—Gabapentin—migraine	0.00121	0.00209	CcSEcCtD
Methyldopa—Oedema—Valproic Acid—migraine	0.00121	0.00209	CcSEcCtD
Methyldopa—Bradycardia—Topiramate—migraine	0.00121	0.00209	CcSEcCtD
Methyldopa—ADRA2A—head—migraine	0.00121	0.013	CbGeAlD
Methyldopa—Infection—Valproic Acid—migraine	0.0012	0.00208	CcSEcCtD
Methyldopa—Hepatitis—Topiramate—migraine	0.00119	0.00205	CcSEcCtD
Methyldopa—Nervous system disorder—Valproic Acid—migraine	0.00119	0.00205	CcSEcCtD
Methyldopa—Thrombocytopenia—Valproic Acid—migraine	0.00119	0.00205	CcSEcCtD
Methyldopa—Vomiting—Propranolol—migraine	0.00118	0.00204	CcSEcCtD
Methyldopa—ADRA2A—Regulation of insulin secretion—CACNA1A—migraine	0.00118	0.0223	CbGpPWpGaD
Methyldopa—Skin disorder—Valproic Acid—migraine	0.00118	0.00203	CcSEcCtD
Methyldopa—Rash—Propranolol—migraine	0.00117	0.00202	CcSEcCtD
Methyldopa—Dermatitis—Propranolol—migraine	0.00117	0.00202	CcSEcCtD
Methyldopa—Diarrhoea—Verapamil—migraine	0.00117	0.00202	CcSEcCtD
Methyldopa—Connective tissue disorder—Topiramate—migraine	0.00117	0.00202	CcSEcCtD
Methyldopa—ADRA2A—nervous system—migraine	0.00115	0.0123	CbGeAlD
Methyldopa—ADRA2A—Amine ligand-binding receptors—HTR1B—migraine	0.00113	0.0214	CbGpPWpGaD
Methyldopa—Dizziness—Verapamil—migraine	0.00113	0.00195	CcSEcCtD
Methyldopa—Myalgia—Timolol—migraine	0.00112	0.00194	CcSEcCtD
Methyldopa—Arthralgia—Timolol—migraine	0.00112	0.00194	CcSEcCtD
Methyldopa—Unspecified disorder of skin and subcutaneous tissue—Timolol—migraine	0.00112	0.00193	CcSEcCtD
Methyldopa—ADRA2A—central nervous system—migraine	0.0011	0.0119	CbGeAlD
Methyldopa—Musculoskeletal discomfort—Valproic Acid—migraine	0.0011	0.0019	CcSEcCtD
Methyldopa—Cardiac disorder—Topiramate—migraine	0.0011	0.0019	CcSEcCtD
Methyldopa—Nausea—Propranolol—migraine	0.0011	0.0019	CcSEcCtD
Methyldopa—Leukopenia—Gabapentin—migraine	0.0011	0.0019	CcSEcCtD
Methyldopa—ADRA2A—Monoamine GPCRs—HTR7—migraine	0.0011	0.0207	CbGpPWpGaD
Methyldopa—ADRA2A—Amine ligand-binding receptors—HTR1A—migraine	0.00109	0.0206	CbGpPWpGaD
Methyldopa—Paraesthesia—Valproic Acid—migraine	0.00109	0.00188	CcSEcCtD
Methyldopa—Vomiting—Verapamil—migraine	0.00109	0.00187	CcSEcCtD
Methyldopa—ADRA2A—cerebellum—migraine	0.00108	0.0116	CbGeAlD
Methyldopa—Angiopathy—Topiramate—migraine	0.00108	0.00186	CcSEcCtD
Methyldopa—Oedema—Timolol—migraine	0.00108	0.00186	CcSEcCtD
Methyldopa—Rash—Verapamil—migraine	0.00108	0.00186	CcSEcCtD
Methyldopa—Dermatitis—Verapamil—migraine	0.00108	0.00186	CcSEcCtD
Methyldopa—Mediastinal disorder—Topiramate—migraine	0.00107	0.00185	CcSEcCtD
Methyldopa—Infection—Timolol—migraine	0.00107	0.00185	CcSEcCtD
Methyldopa—Headache—Verapamil—migraine	0.00107	0.00185	CcSEcCtD
Methyldopa—DDC—SIDS Susceptibility Pathways—HTR1A—migraine	0.00106	0.02	CbGpPWpGaD
Methyldopa—COMT—Neuronal System—CACNA1A—migraine	0.00106	0.02	CbGpPWpGaD
Methyldopa—Nervous system disorder—Timolol—migraine	0.00106	0.00182	CcSEcCtD
Methyldopa—ADRA2A—Amine ligand-binding receptors—HTR2C—migraine	0.00105	0.0199	CbGpPWpGaD
Methyldopa—Myalgia—Gabapentin—migraine	0.00105	0.00181	CcSEcCtD
Methyldopa—Arthralgia—Gabapentin—migraine	0.00105	0.00181	CcSEcCtD
Methyldopa—Skin disorder—Timolol—migraine	0.00105	0.00181	CcSEcCtD
Methyldopa—Gastrointestinal disorder—Valproic Acid—migraine	0.00105	0.0018	CcSEcCtD
Methyldopa—DDC—SIDS Susceptibility Pathways—TAC1—migraine	0.00104	0.0197	CbGpPWpGaD
Methyldopa—Mental disorder—Topiramate—migraine	0.00104	0.0018	CcSEcCtD
Methyldopa—Unspecified disorder of skin and subcutaneous tissue—Gabapentin—migraine	0.00104	0.00179	CcSEcCtD
Methyldopa—Constipation—Valproic Acid—migraine	0.00104	0.00179	CcSEcCtD
Methyldopa—DDC—SIDS Susceptibility Pathways—SLC6A4—migraine	0.00102	0.0194	CbGpPWpGaD
Methyldopa—Flatulence—Topiramate—migraine	0.00102	0.00176	CcSEcCtD
Methyldopa—Nausea—Verapamil—migraine	0.00101	0.00175	CcSEcCtD
Methyldopa—Oedema—Gabapentin—migraine	0.001	0.00173	CcSEcCtD
Methyldopa—Infection—Gabapentin—migraine	0.000997	0.00172	CcSEcCtD
Methyldopa—Nervous system disorder—Gabapentin—migraine	0.000984	0.0017	CcSEcCtD
Methyldopa—Thrombocytopenia—Gabapentin—migraine	0.000983	0.0017	CcSEcCtD
Methyldopa—Musculoskeletal discomfort—Timolol—migraine	0.000982	0.00169	CcSEcCtD
Methyldopa—Skin disorder—Gabapentin—migraine	0.000975	0.00168	CcSEcCtD
Methyldopa—Paraesthesia—Timolol—migraine	0.000968	0.00167	CcSEcCtD
Methyldopa—Body temperature increased—Valproic Acid—migraine	0.000957	0.00165	CcSEcCtD
Methyldopa—Gastrointestinal disorder—Timolol—migraine	0.00093	0.00161	CcSEcCtD
Methyldopa—Leukopenia—Topiramate—migraine	0.000926	0.0016	CcSEcCtD
Methyldopa—ADRA2A—Integration of energy metabolism—CACNA1A—migraine	0.000926	0.0175	CbGpPWpGaD
Methyldopa—ADRA2A—Amine ligand-binding receptors—HTR7—migraine	0.000922	0.0174	CbGpPWpGaD
Methyldopa—Musculoskeletal discomfort—Gabapentin—migraine	0.000914	0.00158	CcSEcCtD
Methyldopa—Paraesthesia—Gabapentin—migraine	0.000901	0.00156	CcSEcCtD
Methyldopa—Hypersensitivity—Valproic Acid—migraine	0.000892	0.00154	CcSEcCtD
Methyldopa—Arthralgia—Topiramate—migraine	0.000881	0.00152	CcSEcCtD
Methyldopa—Myalgia—Topiramate—migraine	0.000881	0.00152	CcSEcCtD
Methyldopa—ADRA2A—brain—migraine	0.000877	0.00942	CbGeAlD
Methyldopa—Unspecified disorder of skin and subcutaneous tissue—Topiramate—migraine	0.000875	0.00151	CcSEcCtD
Methyldopa—Asthenia—Valproic Acid—migraine	0.000869	0.0015	CcSEcCtD
Methyldopa—Gastrointestinal disorder—Gabapentin—migraine	0.000866	0.0015	CcSEcCtD
Methyldopa—Constipation—Gabapentin—migraine	0.000858	0.00148	CcSEcCtD
Methyldopa—DDC—Circadian rythm related genes—NPS—migraine	0.000853	0.0161	CbGpPWpGaD
Methyldopa—Body temperature increased—Timolol—migraine	0.000852	0.00147	CcSEcCtD
Methyldopa—Oedema—Topiramate—migraine	0.000844	0.00146	CcSEcCtD
Methyldopa—SLC15A1—Transmembrane transport of small molecules—TRPM8—migraine	0.000844	0.0159	CbGpPWpGaD
Methyldopa—Infection—Topiramate—migraine	0.000839	0.00145	CcSEcCtD
Methyldopa—DDC—Circadian rythm related genes—SLC6A4—migraine	0.000836	0.0158	CbGpPWpGaD
Methyldopa—Diarrhoea—Valproic Acid—migraine	0.000828	0.00143	CcSEcCtD
Methyldopa—Nervous system disorder—Topiramate—migraine	0.000828	0.00143	CcSEcCtD
Methyldopa—Thrombocytopenia—Topiramate—migraine	0.000827	0.00143	CcSEcCtD
Methyldopa—Skin disorder—Topiramate—migraine	0.00082	0.00142	CcSEcCtD
Methyldopa—Dizziness—Valproic Acid—migraine	0.000801	0.00138	CcSEcCtD
Methyldopa—Hypersensitivity—Timolol—migraine	0.000794	0.00137	CcSEcCtD
Methyldopa—Body temperature increased—Gabapentin—migraine	0.000793	0.00137	CcSEcCtD
Methyldopa—Asthenia—Timolol—migraine	0.000773	0.00133	CcSEcCtD
Methyldopa—Vomiting—Valproic Acid—migraine	0.00077	0.00133	CcSEcCtD
Methyldopa—Musculoskeletal discomfort—Topiramate—migraine	0.000769	0.00133	CcSEcCtD
Methyldopa—ADRA2A—Monoamine GPCRs—HTR2A—migraine	0.000768	0.0145	CbGpPWpGaD
Methyldopa—Rash—Valproic Acid—migraine	0.000763	0.00132	CcSEcCtD
Methyldopa—Dermatitis—Valproic Acid—migraine	0.000763	0.00132	CcSEcCtD
Methyldopa—Headache—Valproic Acid—migraine	0.000758	0.00131	CcSEcCtD
Methyldopa—Paraesthesia—Topiramate—migraine	0.000758	0.00131	CcSEcCtD
Methyldopa—DDC—SIDS Susceptibility Pathways—BDNF—migraine	0.000744	0.0141	CbGpPWpGaD
Methyldopa—Hypersensitivity—Gabapentin—migraine	0.000739	0.00128	CcSEcCtD
Methyldopa—Diarrhoea—Timolol—migraine	0.000737	0.00127	CcSEcCtD
Methyldopa—DDC—Circadian rythm related genes—HTR7—migraine	0.000733	0.0138	CbGpPWpGaD
Methyldopa—Gastrointestinal disorder—Topiramate—migraine	0.000729	0.00126	CcSEcCtD
Methyldopa—Constipation—Topiramate—migraine	0.000722	0.00125	CcSEcCtD
Methyldopa—Asthenia—Gabapentin—migraine	0.00072	0.00124	CcSEcCtD
Methyldopa—Nausea—Valproic Acid—migraine	0.000719	0.00124	CcSEcCtD
Methyldopa—Dizziness—Timolol—migraine	0.000713	0.00123	CcSEcCtD
Methyldopa—Diarrhoea—Gabapentin—migraine	0.000687	0.00119	CcSEcCtD
Methyldopa—Vomiting—Timolol—migraine	0.000685	0.00118	CcSEcCtD
Methyldopa—Rash—Timolol—migraine	0.00068	0.00117	CcSEcCtD
Methyldopa—Dermatitis—Timolol—migraine	0.000679	0.00117	CcSEcCtD
Methyldopa—Headache—Timolol—migraine	0.000675	0.00117	CcSEcCtD
Methyldopa—Body temperature increased—Topiramate—migraine	0.000668	0.00115	CcSEcCtD
Methyldopa—Dizziness—Gabapentin—migraine	0.000664	0.00115	CcSEcCtD
Methyldopa—ADRA2A—Amine ligand-binding receptors—HTR2A—migraine	0.000646	0.0122	CbGpPWpGaD
Methyldopa—Nausea—Timolol—migraine	0.00064	0.0011	CcSEcCtD
Methyldopa—SLC15A1—Transmembrane transport of small molecules—ATP1A3—migraine	0.00064	0.0121	CbGpPWpGaD
Methyldopa—SLC15A1—Transmembrane transport of small molecules—ATP1A2—migraine	0.00064	0.0121	CbGpPWpGaD
Methyldopa—Vomiting—Gabapentin—migraine	0.000638	0.0011	CcSEcCtD
Methyldopa—Rash—Gabapentin—migraine	0.000633	0.00109	CcSEcCtD
Methyldopa—Dermatitis—Gabapentin—migraine	0.000632	0.00109	CcSEcCtD
Methyldopa—Headache—Gabapentin—migraine	0.000629	0.00109	CcSEcCtD
Methyldopa—DDC—SIDS Susceptibility Pathways—HTR2A—migraine	0.000628	0.0119	CbGpPWpGaD
Methyldopa—Hypersensitivity—Topiramate—migraine	0.000622	0.00107	CcSEcCtD
Methyldopa—Asthenia—Topiramate—migraine	0.000606	0.00105	CcSEcCtD
Methyldopa—Nausea—Gabapentin—migraine	0.000596	0.00103	CcSEcCtD
Methyldopa—Diarrhoea—Topiramate—migraine	0.000578	0.000997	CcSEcCtD
Methyldopa—Dizziness—Topiramate—migraine	0.000558	0.000964	CcSEcCtD
Methyldopa—SLC15A1—Transmembrane transport of small molecules—HTR3A—migraine	0.000544	0.0103	CbGpPWpGaD
Methyldopa—Vomiting—Topiramate—migraine	0.000537	0.000927	CcSEcCtD
Methyldopa—Rash—Topiramate—migraine	0.000532	0.000919	CcSEcCtD
Methyldopa—Dermatitis—Topiramate—migraine	0.000532	0.000918	CcSEcCtD
Methyldopa—Headache—Topiramate—migraine	0.000529	0.000913	CcSEcCtD
Methyldopa—Nausea—Topiramate—migraine	0.000502	0.000866	CcSEcCtD
Methyldopa—ADRA2A—G alpha (i) signalling events—HTR1D—migraine	0.000462	0.00874	CbGpPWpGaD
Methyldopa—ADRA2A—GPCRs, Class A Rhodopsin-like—HTR1D—migraine	0.000429	0.00811	CbGpPWpGaD
Methyldopa—ADRA2A—GPCRs, Class A Rhodopsin-like—HTR2B—migraine	0.000399	0.00754	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR ligand binding—CALCRL—migraine	0.000385	0.00728	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR ligand binding—RAMP1—migraine	0.000385	0.00728	CbGpPWpGaD
Methyldopa—ADRA2A—Class A/1 (Rhodopsin-like receptors)—HTR1D—migraine	0.000368	0.00695	CbGpPWpGaD
Methyldopa—ADRA2A—Class A/1 (Rhodopsin-like receptors)—HTR2B—migraine	0.000342	0.00646	CbGpPWpGaD
Methyldopa—DDC—Metabolism—CACNA1A—migraine	0.0003	0.00567	CbGpPWpGaD
Methyldopa—ADRA2A—G alpha (i) signalling events—HTR1B—migraine	0.00028	0.0053	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR ligand binding—HTR1D—migraine	0.00028	0.00529	CbGpPWpGaD
Methyldopa—DDC—SIDS Susceptibility Pathways—TNF—migraine	0.00027	0.00511	CbGpPWpGaD
Methyldopa—ADRA2A—G alpha (i) signalling events—HTR1A—migraine	0.00027	0.0051	CbGpPWpGaD
Methyldopa—COMT—Metabolism—CACNA1A—migraine	0.000266	0.00504	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR ligand binding—HTR2B—migraine	0.00026	0.00492	CbGpPWpGaD
Methyldopa—ADRA2A—GPCRs, Class A Rhodopsin-like—HTR1B—migraine	0.00026	0.00491	CbGpPWpGaD
Methyldopa—ADRA2A—GPCRs, Class A Rhodopsin-like—HTR1A—migraine	0.00025	0.00473	CbGpPWpGaD
Methyldopa—ADRA2A—GPCRs, Class A Rhodopsin-like—HTR2C—migraine	0.000242	0.00457	CbGpPWpGaD
Methyldopa—ADRA2A—GPCRs, Class A Rhodopsin-like—EDNRA—migraine	0.000235	0.00444	CbGpPWpGaD
Methyldopa—ADRA2A—Class A/1 (Rhodopsin-like receptors)—HTR1B—migraine	0.000223	0.00421	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—RAMP1—migraine	0.000218	0.00412	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—CALCRL—migraine	0.000218	0.00412	CbGpPWpGaD
Methyldopa—ADRA2A—Class A/1 (Rhodopsin-like receptors)—HTR1A—migraine	0.000214	0.00405	CbGpPWpGaD
Methyldopa—ADRA2A—GPCRs, Class A Rhodopsin-like—HTR7—migraine	0.000212	0.004	CbGpPWpGaD
Methyldopa—ADRA2A—Class A/1 (Rhodopsin-like receptors)—NPS—migraine	0.000211	0.00399	CbGpPWpGaD
Methyldopa—ADRA2A—Class A/1 (Rhodopsin-like receptors)—TAC1—migraine	0.000211	0.00399	CbGpPWpGaD
Methyldopa—ADRA2A—Class A/1 (Rhodopsin-like receptors)—HTR2C—migraine	0.000207	0.00391	CbGpPWpGaD
Methyldopa—ADRA2A—Class A/1 (Rhodopsin-like receptors)—EDNRA—migraine	0.000201	0.00381	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—CALCRL—migraine	0.000198	0.00374	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—RAMP1—migraine	0.000198	0.00374	CbGpPWpGaD
Methyldopa—ADRA2A—Class A/1 (Rhodopsin-like receptors)—HTR7—migraine	0.000181	0.00343	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR ligand binding—HTR1B—migraine	0.00017	0.00321	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR ligand binding—HTR1A—migraine	0.000163	0.00309	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR ligand binding—TAC1—migraine	0.000161	0.00304	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR ligand binding—NPS—migraine	0.000161	0.00304	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—HTR1D—migraine	0.000158	0.00299	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR ligand binding—HTR2C—migraine	0.000158	0.00298	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR ligand binding—EDNRA—migraine	0.000153	0.0029	CbGpPWpGaD
Methyldopa—ADRA2A—GPCRs, Class A Rhodopsin-like—HTR2A—migraine	0.000148	0.0028	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR ligand binding—CALCA—migraine	0.000148	0.00279	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—HTR2B—migraine	0.000147	0.00278	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—HTR1D—migraine	0.000144	0.00272	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR ligand binding—HTR7—migraine	0.000138	0.00261	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—HTR2B—migraine	0.000134	0.00252	CbGpPWpGaD
Methyldopa—ADRA2A—Class A/1 (Rhodopsin-like receptors)—HTR2A—migraine	0.000127	0.0024	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—RAMP1—migraine	0.000117	0.00221	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—CALCRL—migraine	0.000117	0.00221	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—CACNA1A—migraine	0.000106	0.002	CbGpPWpGaD
Methyldopa—DDC—Metabolism—MTHFR—migraine	9.93e-05	0.00188	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR ligand binding—HTR2A—migraine	9.67e-05	0.00183	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—HTR1B—migraine	9.59e-05	0.00181	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—HTR1A—migraine	9.23e-05	0.00174	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—TAC1—migraine	9.09e-05	0.00172	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—NPS—migraine	9.09e-05	0.00172	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—HTR2C—migraine	8.91e-05	0.00168	CbGpPWpGaD
Methyldopa—COMT—Metabolism—MTHFR—migraine	8.81e-05	0.00167	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—HTR1B—migraine	8.71e-05	0.00165	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—EDNRA—migraine	8.67e-05	0.00164	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—HTR1D—migraine	8.49e-05	0.0016	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—HTR1A—migraine	8.38e-05	0.00158	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—CALCA—migraine	8.35e-05	0.00158	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—NPS—migraine	8.25e-05	0.00156	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—TAC1—migraine	8.25e-05	0.00156	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—HTR2C—migraine	8.09e-05	0.00153	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—HTR2B—migraine	7.89e-05	0.00149	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—EDNRA—migraine	7.87e-05	0.00149	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—HTR7—migraine	7.81e-05	0.00148	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—CALCA—migraine	7.58e-05	0.00143	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—HTR7—migraine	7.09e-05	0.00134	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—LRP1—migraine	6.95e-05	0.00131	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—HTR2A—migraine	5.47e-05	0.00103	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—NOTCH4—migraine	5.33e-05	0.00101	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—HTR1B—migraine	5.14e-05	0.000972	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—HTR2A—migraine	4.96e-05	0.000938	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—HTR1A—migraine	4.95e-05	0.000936	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—NPS—migraine	4.88e-05	0.000921	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—PGR—migraine	4.88e-05	0.000921	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—TAC1—migraine	4.88e-05	0.000921	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—HTR2C—migraine	4.78e-05	0.000904	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—EDNRA—migraine	4.65e-05	0.000879	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—NOTCH3—migraine	4.53e-05	0.000857	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—CALCA—migraine	4.48e-05	0.000846	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—HTR7—migraine	4.19e-05	0.000791	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—TGFBR2—migraine	3.61e-05	0.000682	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—MTHFR—migraine	3.5e-05	0.000662	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—HTR2A—migraine	2.93e-05	0.000554	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—ESR1—migraine	2.6e-05	0.000492	CbGpPWpGaD
